| Ytd | 2.57% | |
| 1y | 31.61% |
| Open | 50.11 | Prev Close | 50.90 | Low | 49.86 | High | 50.46 | Mkt Cap | 100.78B |
| Vol | 4.09M | Avg Vol | 3.98M | EPS | 4.63 | P/E | 10.86 | Forward P/E | 9.79 |
| Beta | 0.29 | Short Ratio | 3.24 | Inst. Own | 18.72% | Dividend | 1.82 | Div Yield | 3.48 |
| Ex Div Date | 08-14 | Earning | 07-28 | 50-d Avg | 51.77 | 200-d Avg | 51.88 | 1yr Est | 58.08 |
GSK News
President Donald Trump's latest executive order calls for splitting the measles, mumps and rubella,
During market turbulence, investors turn to dividend-yielding stocks. Benzinga provides analyst rati
President Donald Trump signed an order Monday limiting core childhood vaccine recommendations to 11
https://youtu.be/H_RititNE8U
The Trump administration is reportedly considering an executive order on vaccines and autism as earl
Vaccine maker GlaxoSmithKline Pharmaceuticals reported a 15.7% rise in first-quarter profit on Monda
British biotech firm Relation Therapeutics said on Wednesday it had entered into a research collab
GSK beats Q2 earnings and revenue estimates, reaffirms 2026 guidance and unveils a new cost-saving p
https://www.gsk.com/en-gb/media/press-releases/cabenuva-demonstrates-superiority-to-daily-oral-thera
GSK plc (GSK) Q2 2026 Earnings Call Transcript
GSK NYSE: GSK reported second-quarter sales growth of 5% at constant exchange rates to more than £8.
GSK beats Q2 revenue and earnings estimates, launches a $2.52B cost-savings program, and updates its
GSK delivered healthy Q2 and H1 2026 results, with the highlight being core turnover and EPS growth
GSK PLC (LSE:GSK, NYSE:GSK) shares jumped to a three-month high after the drugmaker beat second-quar
GSK PLC (LSE:GSK, NYSE:GSK) shares jumped to a three-month high after the drugmaker beat second-quar
U.S. stocks mixed, Dow Jones up 300 points. Shares of Sherwin-Williams rose 7.8% after reporting bet
GSK (GSK) came out with quarterly earnings of $1.36 per share, beating the Zacks Consensus Estimate
The U.K. drugmaker is targeting annual savings of $2.52 billion by 2029, as Chief Executive Luke Mie
In times of market turbulence, dividend-yielding stocks are popular for investors. Check out analyst
GSK (NYSE:GSK) affirms FY2026 Adj EPS guidance from $4.90-$5.00 to $4.90-$5.00 vs $4.79 analyst esti
GSK (NYSE:GSK) reported quarterly earnings of $1.35 per share which beat the analyst consensus estim
Results add to a growing body of positive late-stage evidence for Ris-Rez, including recent pivotal
GSK on Tuesday beat second-quarter profit expectations and launched a £1.9 billion ($2.52 billion
British drugmaker GSK said on Tuesday that it will invest £400 million ($531.12 million) over 3 year
GSK on Tuesday said partner Hansoh Pharmaceutical's experimental drug Ris-Rez met its main goa
Bank of New York Mellon Corp lowered its position in GSK PLC Sponsored ADR (NYSE: GSK) by 13.8% duri
GSK Canada today announced the approval of Shingrix (GSK's Recombinant Zoster Vaccine or RZV) in
The FTSE 100 Index was little changed this week as investors assessed the escalating UK-Iran crisis,
Summit announces updated HARMONi overall survival data and partners with Arcus to test ivonescimab i
GSK secures early FDA approval for Jideytro, its first lung cancer therapy, backed by strong ARROS-1
GSK's Specialty Medicines unit is expected to post double-digit CER growth in Q2, driven by newer HI
Approval based on ARROS-1 phase I/II trial demonstrating meaningful and durable responses in patient
GSK wins early FDA approval for Jideytro, a targeted treatment for adults with advanced ROS1-positiv
GSK plc (LSE/NYSE:GSK) today announced the US Food and Drug Administration (FDA) has approved Jideyt
Trump says imported generic drugs face 0% tariffs for 2 years, before 100% and then 200% duties.
GSK stops development of chronic cough drug camlipixant after mixed Phase 3 results; continue testin
Investors turn to dividend-yielding stocks during market turbulence. Benzinga's Analyst Stock Ra
GSK Jemperli shows sustained complete responses in dMMR/MSI-H rectal cancer, potentially eliminating
During market turbulence, investors turn to dividend-yielding stocks. Benzinga offers latest analyst
The Nasdaq 100 sank 3.3% Tuesday as AI and optical stocks cratered, while cash rotated into real est
AnaptysBio shares jump 12% after a favorable Delaware Court ruling in the Tesaro dispute. See the la
Ruling preserves current contracted royalty rates and rejects Tesaro's request for any royalty r
AnaptysBio, Inc. (Nasdaq: ANAB) today announced that its Board of Directors has authorized a Stock R
Here's a look at this week's earnings calendar, featuring over 100 S&P 500 members.
AnaptysBio asks a Delaware court to dismiss Tesaro's breach claim, citing anti-SLAPP law in a di
On November 20, 2025, as previously announced, AnaptysBio, Inc. ("AnaptysBio") filed a Verif